Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

Hypertension Clinical Trial

— ANDORRA  

Official title:

Optimum and Stepped Care Standardised Antihypertensive Treatment With or Without Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. ANDORRA TRIAL

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02539810
• Other study ID #: P140914
• Secondary ID: P140914
• Status: Terminated
• Phase: Phase 4
• First received: July 28, 2015
• Last updated: January 24, 2018
• Start date: September 2015
• Est. completion date: July 2017

Study information

• Verified date: January 2018
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The ANDORRA study is a, multicenter, prospective, open, randomized, controlled blinded endpoint trial (PROBE) comparing two treatment strategies (renal artery stenting + standardized and optimized medical treatment [SOMT] versus SOMT alone) of 12 months duration in patients with confirmed resistant hypertension (RH) and angiographically proven grade III unilateral or bilateral atherosclerotic renal artery stenosis (ARAS) ≥ 60%.

Description:

All eligible patients diagnosed with RH on office BP measurements and unilateral or bilateral ARAS ≥60% on a non-invasive test (CT-angiogram or MR-angiogram) will receive a standardized optimized triple antihypertensive treatment for 4 weeks. After 4 weeks, patients with confirmed RH by ABPM (daytime ABPM ≥ 135 or 85 mmHg) and no clinically significant increase in plasma creatinine from baseline (< 30%) will undergo a renal angiogram to confirm the degree of ARAS ≥60% in diameter.

Immediately after the renal angiography, all patients will undergo flow fractional reserve (FFR) measurements. Once FFR measurements have been done and all criteria are met, patients will be randomized in the angiography room to either renal artery stenting + SOMT (stenting group) versus SOMT (control group) whatever the results of the FFR in a 1:1 ratio. Both groups will continue the SOMT during follow-up.

The SOMT will be prescribed from the inclusion visit until the 6 month-visit after randomization. After randomization, the antihypertensive treatment will be adapted according to the results of home BP (HBP) at monthly visits starting 2 months after randomization. After the 6-month visit, the antihypertensive treatment adaptation will be left at the discretion of the physician in charge of the patient.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: July 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age: 40 to 80 Years

• Men or women

• Supine office BP = 140 and/or 90 mmHg at screening despite a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive treatments of different classes, including a diuretic.

• Unilateral or bilateral ARAS of a main renal artery =60% diagnosed by renal CT- angiogram (or MR-angiogram if there is a contraindication to perform CT) performed in the year before

• One or two functional kidney(s) = 70 mm in pole-to-pole length

• eGFR = 20 ml/min/1.73 m² (MDRD formula)

• Signed informed consent

• Social insurance coverage

Inclusion criteria for the renal angiogram procedure:

• RH confirmed by daytime ABPM = 135 or 85 mmHg after 1 month treatment with SOMT at Visit V1.

Inclusion criteria for the randomization:

• Unilateral or bilateral ARAS of a main renal artery = 60% confirmed on renal angiogram by Quantitative Vascular Analysis (QVA)

• Increase in plasma creatinine < 30% after 4-week SOMT

Exclusion Criteria:

• Fibromuscular dysplasia of renal artery or other non-atherosclerotic renal artery stenosis

• Other secondary form of hypertension excluded on the basis of a clinical, hormonological and/or imaging work-up

• Restenosis after a previous renal angioplasty or stenting

• Only a stenosis of an accessory renal artery supplying <1/2 of the ipsilateral renal parenchyma

• Additional indication of ARAS stenting (Malignant hypertension, = 30% increase in plasma creatinine after renin angiotensin system (RAS) blocker or after RAS blocker and diuretic administration, flash pulmonary edema)

• Kidney pole-to-pole length < 70 mm

• Vascular disease precluding access for stenting

• Abrupt vessel closure or dissection after diagnostic angiography

• Contraindication to renal artery stenting according the notice for use of the stents

• eGFR < 20 ml/min/1.73 m² (MDRD)

• History of transient ischemic accident (TIA) or cerebrovascular accident (CVA) during the 3 months prior to visit 1

• History of acute heart failure or heart failure (NYHA class III-IV) within the 3 months prior to visit 1

• History of myocardial infarction, unstable angina, coronary bypass or percutaneous coronary angioplasty during the 3 months prior to visit 1

• Abdominal aortic aneurysm with indication for surgery or EVAR (Endovascular Aneurysm Repair)

• Known history of cholesterol embolism

• Brachial circumference of = 42 cm

• Severe contrast media allergy, not amenable to pre-treatment

• Allergy to aspirin or clopidogrel

• Atrial fibrillation

• Comorbid condition causing life expectancy = 3 years

• Unlikely to co-operate in the study and/or poor compliance anticipated by the investigator

• Participant not affiliated to the French social security

• Pregnancy or breastfeeding

• Guardianship for incapacity

Related Conditions & MeSH terms

• Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent
• Constriction, Pathologic
• Coronary Vasospasm
• Hypertension
• Hypertension Resistant to Conventional Therapy
• Renal Artery Obstruction

Intervention

Device:
• Renal artery Angioplasty plus stenting.
renal artery stenting

Drug:
• Anti hypertensive, statin and antiplatelet medication.
Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.

Locations

Country	Name	City	State
France	Hopital Saint Andre - CHU Bordeaux	Bordeaux	Gironde
France	CHU Clermont-Ferrand	Clermont-Ferrand	Puy-de-Dome
France	Hopital Arthur Gardiner	Dinard	Ille-et-Vilaine
France	Groupe Hospitalier Mutualiste	Grenoble	Isere
France	Hopital Michallon - CHU Grenoble	La Tronche	Isere
France	Hopital Cardiologique - CHRU Lille	Lille	Nord
France	Hopital de la Croix-Rousse - CHU Lyon	Lyon	Rhone
France	Hopital Lapeyronie - CHU Montpellier	Montpellier	Herault
France	Hopital Pasteur	Nice	Alpes-Maritimes
France	Hopital de la Pitie Salpetriere	Paris
France	Hopital Europeen Georges Pompidou (HEGP)	Paris
France	Hopital Pontchaillou - CHU Rennes	Rennes	Ille-et-Vilaine
France	Hopital Rangueil - CHU Toulouse	Toulouse	Haute-Garonne
France	Hopital de Brabois	Vandoeuvre les Nancy	Meurthe-et-Moselle
France	Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu	Vandoeuvre les Nancy	Meurthe-et-Moselle

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in diurnal systolic blood pressure assessed by ambulatory BP monitoring (ABPM)		Baseline to 6 months
Secondary	Adverse events of renal artery stenting		Baseline to 12 months
Secondary	Change in average 24-hour and nighttime Systolic Blood Pressure by ABPM		Baseline to 12 months
Secondary	Change in average 24-hour, daytime and nighttime diastolic Blood Pressure by ABPM		Baseline to 12 months
Secondary	Change in Systolic/diastolic Blood Pressure by home blood pressure monitoring		Baseline to 12 months
Secondary	Change in office Systolic/diastolic Blood Pressure		Baseline to 12 months
Secondary	Antihypertensive medication score		Baseline to 12 months
Secondary	Detection of the drugs in urine by LC-MS/MS		Baseline to 12 months
Secondary	Renal artery restenosis in patients of the stenting group assessed by duplex ultrasound and/or renal CTA		Baseline to 12 months
Secondary	Adverse cardiovascular (CV) events		Baseline to 12 months
Secondary	Change in plasma creatinine and eGFR		Baseline to 12 months
Secondary	Clinical renal events: renal death, progressive renal insufficiency (i.e. need for dialysis), need for permanent renal replacement therapy, need of target vessel stenting in the SOMT group (number of crossovers)		Baseline to 12 months